Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
CAMBRIDGE, Mass., Oct. 31, 2016 -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that senior company leaders will present at key November investor healthcare conferences, including the 25th Annual Credit Suisse Healthcare Conference and the Jefferies 2016 London Healthcare Conference.
Details of the upcoming presentations are as follows:
Monday, November 7th
25th Annual Credit Suisse Healthcare Conference, 2016
Location: Scottsdale, Arizona
Presentation Time: 11:30 AM MST
Thursday, November 17th
Jefferies 2016 London Healthcare Conference
Location: London, England
Presentation Time: 3:20 PM GMT
Individuals may access the presentations for each conference via live webcast on the Intellia website at www.intelliatx.com under "Events & Presentations" in the "Investor Relations" section. A replay of the webcast will be available on this site for 90 days following the live event.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.
Media Contact: Jennifer Mound Smoter Chief External Affairs & Communications Officer +1 857-706-1071 [email protected] Investor Contacts: John Graziano Trout Group +1 646-378-2942 [email protected] Chad Rubin Trout Group +1 646-378-2947 [email protected]
